$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000157056219000131 Filed on August 12, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q2
Revenue	$13.17M	$2.311M	$0.00
YoY Change
Cost Of Revenue	$3.718M	$660.0K	$0.00
YoY Change
Gross Profit	$9.449M	$1.651M	$0.00
YoY Change
Gross Profit Margin	71.76%	71.44%
Selling, General & Admin	$30.90M	$34.89M	$6.248M
YoY Change	328.59%	458.45%	681.0%
% of Gross Profit	326.99%	2113.39%
Research & Development	$693.0K	$509.0K	$1.648M
YoY Change	-64.95%	-69.11%	20.73%
% of Gross Profit	7.33%	30.83%
Depreciation & Amortization	$1.202M	$978.0K	$0.00
YoY Change	39966.67%		-100.0%
% of Gross Profit	12.72%	59.24%
Operating Expenses	$34.59M	$37.65M	$16.10M
YoY Change	201.04%	133.84%	607.69%
Operating Profit	-$25.14M	-$36.00M	-$16.10M
YoY Change	118.8%	123.58%	607.69%
Interest Expense	-$2.000M	-$1.800M	-$320.0K
YoY Change	525.0%	462.5%
% of Operating Profit
Other Income/Expense, Net	-$2.455M	-$2.412M	-$321.0K
YoY Change	662.42%	651.4%	32000.0%
Pretax Income	-$27.13M	-$37.79M	-$16.42M
YoY Change	129.73%	130.16%	621.49%
Income Tax	-$149.0K	-$227.0K	$12.00K
% Of Pretax Income
Net Earnings	-$26.98M	-$37.57M	-$16.43M
YoY Change	128.1%	128.61%	615.72%
Net Earnings / Revenue	-204.94%	-1625.57%
Basic Earnings Per Share
Diluted Earnings Per Share	-$982.2K	-$1.371M	-$693.5K
COMMON SHARES
Basic Shares Outstanding	27.42M shares	27.33M shares	23.64M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$74.03M	$99.93M	$43.60M
YoY Change	-29.63%	129.19%
Cash & Equivalents	$39.12M	$30.29M	$43.60M
Short-Term Investments	$34.91M	$69.64M
Other Short-Term Assets	$3.900M	$3.000M	$1.000M
YoY Change	333.33%	200.0%	900.0%
Inventory	$10.04M	$11.52M
Prepaid Expenses
Receivables	$7.206M	$1.410M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$95.18M	$115.8M	$44.62M
YoY Change	-10.28%	159.57%	44523.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$984.0K	$290.0K	$5.000K
YoY Change	98300.0%	5700.0%
Goodwill	$21.21M	$21.21M	$21.21M
YoY Change	0.0%	0.0%
Intangibles	$59.86M	$59.21M	$56.08M
YoY Change	6.74%	5.59%
Long-Term Investments
YoY Change
Other Assets	$1.195M	$1.206M	$22.00K
YoY Change		5381.82%	-89.0%
Total Long-Term Assets	$87.48M	$86.96M	$77.31M
YoY Change	13.19%	12.47%	-47.05%
TOTAL ASSETS
Total Short-Term Assets	$95.18M	$115.8M	$44.62M
Total Long-Term Assets	$87.48M	$86.96M	$77.31M
Total Assets	$182.7M	$202.8M	$121.9M
YoY Change	-0.39%	66.3%	-16.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.125M	$7.708M	$751.0K
YoY Change	826.63%	926.36%	50.2%
Accrued Expenses	$14.38M	$15.40M	$2.933M
YoY Change	199.6%	425.06%	877.67%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change
Total Short-Term Liabilities	$25.97M	$23.11M	$3.684M
YoY Change	375.71%	527.17%	-94.69%
LONG-TERM LIABILITIES
Long-Term Debt	$73.18M	$72.86M	$16.50M
YoY Change	335.6%	341.59%	-86.52%
Other Long-Term Liabilities	$48.60M	$47.90M	$48.80M
YoY Change	-4.89%	-1.84%
Total Long-Term Liabilities	$73.18M	$72.86M	$65.30M
YoY Change	7.78%	11.58%	-46.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.97M	$23.11M	$3.684M
Total Long-Term Liabilities	$73.18M	$72.86M	$65.30M
Total Liabilities	$165.6M	$161.6M	$84.00M
YoY Change	87.33%	92.38%	-60.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$198.6M	-$171.6M	-$98.75M
YoY Change	79.55%	73.73%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.04M	$41.18M	$37.93M
YoY Change
Total Liabilities & Shareholders Equity	$182.7M	$202.8M	$121.9M
YoY Change	-0.39%	66.3%	-16.54%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q2
OPERATING ACTIVITIES
Net Income	-$26.98M	-$37.57M	-$16.43M
YoY Change	128.1%	128.61%	615.72%
Depreciation, Depletion And Amortization	$1.202M	$978.0K	$0.00
YoY Change	39966.67%		-100.0%
Cash From Operating Activities	-$25.10M	-$33.16M	-$5.660M
YoY Change	332.76%	485.87%	76.32%
INVESTING ACTIVITIES
Capital Expenditures	-$640.0K	-$1.970M	-$10.00K
YoY Change		19600.0%
Acquisitions
YoY Change
Other Investing Activities	$35.03M	$10.19M
YoY Change
Cash From Investing Activities	$34.39M	$8.230M	-$10.00K
YoY Change		-82400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-460.0K	850.0K	-310.0K
YoY Change	-100.68%	-374.19%	-109.63%
NET CHANGE
Cash From Operating Activities	-25.10M	-33.16M	-5.660M
Cash From Investing Activities	34.39M	8.230M	-10.00K
Cash From Financing Activities	-460.0K	850.0K	-310.0K
Net Change In Cash	8.830M	-24.08M	-5.980M
YoY Change	-85.66%	302.68%	-59900.0%
FREE CASH FLOW
Cash From Operating Activities	-$25.10M	-$33.16M	-$5.660M
Capital Expenditures	-$640.0K	-$1.970M	-$10.00K
Free Cash Flow	-$24.46M	-$31.19M	-$5.650M
YoY Change	321.72%	452.04%	76.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27424480	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	163000	USD
	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	0	USD
CY2018Q4	eols	Accrued Contingent Royalty Obligations Current AccruedContingentRoyaltyObligationsCurrent	0	USD
CY2019Q2	eols	Accrued Contingent Royalty Obligations Current AccruedContingentRoyaltyObligationsCurrent	3396000	USD
CY2019Q2	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	29000	USD
	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	46000	USD
	eols	Amortization Of Discount On Shortterm Investments AmortizationOfDiscountOnShorttermInvestments	0	USD
	eols	Amortization Of Discount On Shortterm Investments AmortizationOfDiscountOnShorttermInvestments	-586000	USD
	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	66998000	USD
	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	0	USD
	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13188000	USD
	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	0	USD
CY2018Q1	eols	Capital Contribution From Parent Forgiveness Of Related Party Borrowings CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings	13188000	USD
CY2018Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	1091000	shares
	eols	Contingent Promissory Note ContingentPromissoryNote	16042000	USD
	eols	Contingent Promissory Note ContingentPromissoryNote	0	USD
	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Milestone Payment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMilestonePayment	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1410000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	760000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	39700000	USD
	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.22
CY2018Q2	eols	Contractual Obligation Noncurrent ContractualObligationNoncurrent	48800000	USD
CY2019Q2	eols	Contractual Obligation Noncurrent ContractualObligationNoncurrent	47169000	USD
CY2018Q1	eols	Deemed Contribution From Parent Increase Of Related Party Receivable DeemedContributionFromParentIncreaseOfRelatedPartyReceivable	1051000	USD
	eols	Deferred Offering Costs Accrued Unpaid DeferredOfferingCostsAccruedUnpaid	22000	USD
	eols	Deferred Offering Costs Accrued Unpaid DeferredOfferingCostsAccruedUnpaid	0	USD
CY2018Q4	eols	Deferred Rent DeferredRent	25000	USD
CY2019Q1	eols	Deferred Rent DeferredRent	25000	USD
CY2018Q2	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Milestone Payment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMilestonePayment	0	USD
CY2019Q2	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Milestone Payment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMilestonePayment	0	USD
	eols	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Milestone Payment FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityMilestonePayment	9213000	USD
	eols	Increasedecrease In Operating Lease Liabilities IncreasedecreaseInOperatingLeaseLiabilities	-5000	USD
	eols	Increasedecrease In Operating Lease Liabilities IncreasedecreaseInOperatingLeaseLiabilities	-409000	USD
CY2019Q2	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	81826000	USD
	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
CY2019Q2	eols	Longterm Debt Maturities Final Payments LongtermDebtMaturitiesFinalPayments	4125000	USD
CY2019Q2	eols	Longterm Debt Maturities Final Payments In Year Five LongtermDebtMaturitiesFinalPaymentsInYearFive	4125000	USD
CY2019Q2	eols	Longterm Debt Maturities Final Payments In Year Four LongtermDebtMaturitiesFinalPaymentsInYearFour	0	USD
CY2019Q2	eols	Longterm Debt Maturities Final Payments In Year Three LongtermDebtMaturitiesFinalPaymentsInYearThree	0	USD
CY2019Q2	eols	Longterm Debt Maturities Principal Payment Excluding Final Payment LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment	75000000	USD
CY2019Q2	eols	Longterm Debt Maturities Principal Payment Excluding Final Payment Due In Year Five LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive	9783000	USD
CY2019Q2	eols	Longterm Debt Maturities Principal Payment Excluding Final Payment Due In Year Four LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour	39130000	USD
CY2019Q2	eols	Longterm Debt Maturities Principal Payment Excluding Final Payment Due In Year Three LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree	26087000	USD
	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	0	USD
	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	2000000	USD
	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	2885000	USD
	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
	eols	Non Cash Note Obligation NonCashNoteObligation	140688000	USD
	eols	Non Cash Note Obligation NonCashNoteObligation	0	USD
	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	68767000	USD
	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	0	USD
	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	73690000	USD
	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	0	USD
	eols	Operating Lease Percentage Of Annual Rent Escalation OperatingLeasePercentageOfAnnualRentEscalation	0.03
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	0	USD
	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	523000	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	0	USD
	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	9213000	USD
	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	-238000	USD
	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	795000	USD
	eols	Provisions Related To Rebates And Coupons ProvisionsRelatedToRebatesAndCoupons	900000	USD
CY2018Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	8200000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	9100000	USD
CY2019Q2	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	1269000	USD
	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	6182000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	210000	USD
CY2019Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1565000	USD
CY2019Q2	eols	Stock Issued During Period Value Issuance Of Common Stock In Connection With Incentive Equity Plan StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan	853000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5276000	USD
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	22074000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1006000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1558000	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7708000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2623000	USD
CY2018Q2	eols	Stock Issued During Period Value Issuance Of Common Stock In Connection With Incentive Equity Plan StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan	-238000	USD
CY2019Q1	eols	Stock Issued During Period Value Issuance Of Common Stock In Connection With Incentive Equity Plan StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan	-58000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2015000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2486000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2623000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3630000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	43000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207408000	USD
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	212704000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	66998000	USD
CY2018Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	0	USD
CY2019Q2	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1387000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	931000	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4653000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2457000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4455000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	428000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	889000	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1400000	USD
CY2018Q4	us-gaap	Assets Assets	171844000	USD
CY2019Q2	us-gaap	Assets Assets	202781000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	94339000	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	115826000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2019Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	69640000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	9100000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6182000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	55000	USD
CY2019Q2	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	1300000	USD
	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	2500000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93162000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30289000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	99900000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43585000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93162000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30289000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	43585000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-62873000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1044840	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27274991	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27393004	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27274991	shares
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-37515000	USD
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27393004	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16433000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22595000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48499000	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	50200000	USD
CY2019Q2	us-gaap	Contractual Obligation ContractualObligation	43773000	USD
CY2018Q1	us-gaap	Contractual Obligation ContractualObligation	39700000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	660000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	660000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	22000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-14750000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15055000	USD
CY2019Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	305000	USD
CY2018Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4000	USD
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	978000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1462000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1462000	USD
CY2018Q1	us-gaap	Dividends Dividends	2002000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.37
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.77
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2577000	USD
CY2019Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3365000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	39700000	USD
CY2018Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	40600000	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	48800000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	50200000	USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	45900000	USD
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	47169000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1407000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	43798000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2092000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2904000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2904000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3330000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4183000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60618000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	59211000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2019Q2	us-gaap	Goodwill Goodwill	21208000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	1651000	USD
	us-gaap	Gross Profit GrossProfit	1651000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	0	USD
	us-gaap	Gross Profit GrossProfit	0	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16421000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22573000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37794000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-63292000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	22000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-227000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14750000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2405000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13347000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11522000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	854000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1997000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59211000	USD
CY2018Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	77284000	USD
CY2019Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	80419000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Interest Paid Net InterestPaidNet	1544000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	11522000	USD
CY2018Q2	us-gaap	Investment Income Net InvestmentIncomeNet	0	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	0	USD
CY2019Q2	us-gaap	Investment Income Net InvestmentIncomeNet	615000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	1004000	USD
CY2019Q2	us-gaap	Lease Cost LeaseCost	327000	USD
	us-gaap	Lease Cost LeaseCost	611000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6754000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1444000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1275000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1221000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1168000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1167000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	479000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1576000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2018Q4	us-gaap	Liabilities Liabilities	87460000	USD
CY2019Q2	us-gaap	Liabilities Liabilities	161600000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	171844000	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	202781000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5276000	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	23105000	USD
CY2019Q2	us-gaap	Long Term Debt LongTermDebt	79125000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	13908000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	39130000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	16904000	USD
CY2019Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	17408000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51459000	USD
CY2018Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	16000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61283000	USD
CY2019Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	26087000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-71798000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72862000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7865000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7900000	USD
CY2018Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2019Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52358000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52400000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6162000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-16433000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-16400000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22595000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-22600000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-10975000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37567000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-37600000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48500000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-48542000	USD
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	16100000	USD
	us-gaap	Operating Expenses OperatingExpenses	22145000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	37648000	USD
	us-gaap	Operating Expenses OperatingExpenses	62917000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16100000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22145000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-35997000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-61266000	USD
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	267000	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	501000	USD
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	100000	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5178000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1031000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	916000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4147000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	138000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	468000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5040000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1029000	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y188D
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	USD
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1206000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	52000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	52000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	43000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-321000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	94011000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-428000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	346000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2412000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3030000	USD
	us-gaap	Payments For Software PaymentsForSoftware	0	USD
	us-gaap	Payments For Software PaymentsForSoftware	2441000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2205000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1177000	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2965000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	56330000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	73906000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	25000000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1127000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	290000	USD
CY2019Q2	us-gaap	Purchase Obligation PurchaseObligation	9700000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1648000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3326000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	509000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2862000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123025000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171600000	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-171567000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2311000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5566000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2311000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6248000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9715000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	34892000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	52411000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3630000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4455000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1086585	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3257801	shares
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3256348	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	217672	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	8.24
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	7.32
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.70
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	870366	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.80
CY2019Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	28000	USD
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	49000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-75543000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	51982000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	37934000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	84384000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	75357000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	41181000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	34500000	USD
CY2019Q2	us-gaap	Variable Lease Cost VariableLeaseCost	32000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	61000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23687866	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21961576	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27408774	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27369691	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company received regulatory approval from the FDA and Health Canada to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> also requires regulatory approval from the European Medicines Agency (“EMA”) and other similar regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates in the jurisdictions where approval is sought, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (“Daewoong”) entered into an agreement (the “Daewoong Agreement”), pursuant to which, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau®) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong’s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional information regarding such litigation.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates</font><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenue, allowance for doubtful accounts, the fair values of financial instruments, intangible assets and goodwill, useful lives of intangible assets, inventory valuation, lease liabilities, and royalty obligations, among others. Although the Company bases these estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div></div>

Files In Submission

Name	View Source	Status
0001570562-19-000131-index-headers.html	Edgar Link	pending
0001570562-19-000131-index.html	Edgar Link	pending
0001570562-19-000131.txt	Edgar Link	pending
0001570562-19-000131-xbrl.zip	Edgar Link	pending
eols-20190630.xml	Edgar Link	completed
eols-20190630.xsd	Edgar Link	pending
eols-20190630_cal.xml	Edgar Link	unprocessable
eols-20190630_def.xml	Edgar Link	unprocessable
eols-20190630_lab.xml	Edgar Link	unprocessable
eols-20190630_pre.xml	Edgar Link	unprocessable
evolus06301910-q.htm	Edgar Link	pending
evolus10106301910-q.htm	Edgar Link	pending
exhibit31106301910q.htm	Edgar Link	pending
exhibit31206301910q.htm	Edgar Link	pending
exhibit32106301910q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2019 Q3 Form 10-Q Financial Statement

#000157056219000131 Filed on August 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2019 Q3 Form 10-Q Financial Statement

#000157056219000131 Filed on August 12, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols